PBAC's latest decision on Nurse practitioner prescribing hepatitis b c hiv: Recommended (2019). Considered for Expansion of prescribing eligibility for Hepatitis B, Hepatitis C, and HIV medicines under the Highly Specialised Drugs (HSD) Program to include authorised nurse practitioners.
PBAC outcome
Recommended
Not applicable
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2019
Submissions
1
2019 → 2019
Eligible population
Authorised nurse practitioners prescribing Hepatitis B, C, and HIV medicines under the HSD program.
Therapy area
Infectious disease
Line of therapy
Not applicable
Evidence base
Other
Economic model
Not modelled
ICER note
Not modelled — administrative/policy change regarding prescriber eligibility, not a drug submission.